British vets may soon have a powerful new weapon in the treatment of dogs suffering atopic dermatitis, as the first monoclonal antibody (mAb) in veterinary medicine has been recommended for marketing authorisation.

The European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) has recommended the granting of a marketing authorisation in the European Union (EU) for Cytopoint from Zoetis.

trafficlight_Fotolia_Paul-FleetCytopoint is a solution for injection containing the new active substance lokivetmab, the first mAb in a veterinary medicine in the EU. It is intended for the treatment of dogs with atopic dermatitis.

Controlled studies

An mAb is an immune protein that recognises and binds to a specific target protein. Lokivetmab is a caninised mAb developed by biotechnology that specifically targets and inhibits canine interleukin-31, an immune protein that plays an important role in atopic dermatitis.

The efficacy of this medicine was evaluated in a number of controlled laboratory and clinical studies. The data showed treatment with Cytopoint reduced itching and the severity of skin disease in dogs receiving the medicine at the proposed dose of 1mg/kg.

The CVMP opinion will be sent to the European Commission (EC) for the adoption of a decision on an EU-wide marketing authorisation. No timeline has been announced for the EC decision that forms the final hurdle to Cytopoint being launched on to the UK market. Cytopoint has already been authorised for use by the US Department of Agriculture.

‘Human quality’ care

Clinton Lewis, Zoetis executive vice-president and president of international operations, said he was “excited” about the potential of Cytopoint, which he described as “…a tangible example of the advances and innovation leadership Zoetis is bringing to the animal health market”.

He suggested, once finally approved for marketing authorisation, Cytopoint would fit the company’s model of providing vets with more “human quality” care for dogs – the “extended members of the family”.

  • Read the full story in the 6 March issue of Veterinary Times.
View your activity >

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz

related content

A study of dog DNA has revealed a genetic mutation linked to flat face shapes, such as those seen in pugs and bulldogs.

2 mins

Veterinary experts, doctors and scientists have come together in a one health coalition to drive the acquisition of knowledge into one of the UK’s most baffling and lethal canine diseases.

4 mins

Heart rate variability is an established risk factor for mortality in both healthy dogs and animals with heart failure, according to a study.

2 mins

Marge Chandler looks at the factors impacting on canine and feline weight gain to help equip VNs with the information they need in battling the pet bulge.

26 mins

Britain’s largest pet insurance firm is reviewing the registration process for its breeder scheme following allegations in a Sunday newspaper.

5 mins

NexGard Spectra is now the only product that prevents lungworm and kills ticks.

3 mins